Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm
NCT07336472
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase I/II, Multicenter, Open-label Study of IBI3003 in Participants With Relapsed or Refractory Multiple Myeloma
Sponsor: Fortvita Biologics (USA)Inc.
Conditions
Multiple Myeloma
Interventions
IBI3003
Updated 1 time since 2026 Last updated: Feb 24, 2026 Started: Apr 1, 2026 Primary completion: Dec 31, 2027 Completion: Sep 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07336472, this PHASE1/PHASE2 trial focuses on Multiple Myeloma and remains actively recruiting participants. Sponsored by Fortvita Biologics (USA)Inc., it has been updated 1 time since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Fortvita Biologics (USA)Inc.
Data source: Fortvita Biologics (USA)Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.